Abstract
Baseline endogenous serum testosterone levels and all-cause mortality in men with prostate cancer treated by radical radiotherapy: 11-year follow-up data.
Author
person
Santhanam Sundar
Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom
info_outline
Santhanam Sundar, Ewan Shawcroft, Lauren Jones, Micheal O'Cathail, Shaymaa Usama Hosni, Jessica Little, Georgina Walker, Ashley Cox, Eamonn Fergusson
Full text
Authors
person
Santhanam Sundar
Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom
info_outline
Santhanam Sundar, Ewan Shawcroft, Lauren Jones, Micheal O'Cathail, Shaymaa Usama Hosni, Jessica Little, Georgina Walker, Ashley Cox, Eamonn Fergusson
Organizations
Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom, Nottingham University Hospitals NHS trust, Nottingham, United Kingdom, St Bartholomew's Hospital, London, United Kingdom, Nottingham University Hospital NHS Trust, Nottingham, United Kingdom, Royal United Hospitals Bath NHS Foundation Trust, Bath, United Kingdom, University of Nottingham, Nottingham, United Kingdom
Abstract Disclosures
Research Funding
No funding received
None.
Background:
Low levels of serum testosterone are associated with higher all-cause mortality and cardiovascular mortality
in some studies
.(PMID: 18040028). But men with low levels of serum testosterone at reduced risk of developing prostate cancer. (PMID: 30077399). In middle-aged and elderly men, single point testosterone measurements have been shown to reliably reflect long term androgen exposure. [PMID: 1548361]. We assessed the interaction of pre-treatment serum testosterone levels and long term all-cause mortality in men with newly diagnosed prostate cancer.
Methods:
Prostate cancer pts enrolled in an ethics approved, prospective study evaluating a rating scale. Baseline serum testosterone levels were measured before the pts were commenced on androgen deprivation therapy and radical radiotherapy. Patient characteristics: Mean age 68.2yrs (median 69yrs); Age range category < 60yrs:14.9% , 61-70yrs:47.3% and > 71 yrs: 37.8%. Charlson Comorbidity Index (CCI) prevalence at baseline as follows CCI- Low risk : 39.9%; CCI-medium risk : 51.4%; CCI-high risk: 8.8%. PSA median level was 10.85 ug/L. Tumour was localised in a majority of pts- stage T1/T2 in 72% . Pts with M1 disease were not enrolled. Histology grade: Gleeson grade 6 in 7.4% and Gleeson grade 7 in 53.4% . Serum testosterone: Median 11.9 nmol/l; Mean 12.4 (Min-Max 2.6 to 26.7). Cox proportional hazards regression used to analyze the effect of baseline Serum Testosterone on long term overall survival, while controlling for covariates (age, cancer T stage, PSA category, Gleeson Category and Charlson Comorbidity index).
Results:
Lower levels of serum testosterone at baseline were associated with decreased all-cause mortality. There was no significant correlation between testosterone levels and age in our study sample of relatively elderly population (Pearson Correlation p = 0.362); There was no correlation testosterone levels and PSA levels(P = 0.821); no association between serum Testosterone levels and Gleeson Grade as well as T stage. (F = 0.78 ; P = 0.46 and F = 1.34 ; P = 0.26 respectively). There was also no significant variation in testosterone levels according to Comorbidity categorised by Charlson Comorbidity Index. (F = 1.31 P = 0 .26).
Conclusions:
Lower Serum testosterone levels were associated with decreased all-cause mortality in this prospectively collected survival data of
non-metastatic
Prostate cancer patients.
SPSS delineated quartiles for
Baseline Serum Teststerone
Median testosterone
(nmol/l)
P values
Cox regression
Exp(B) with
95.0% CI for Exp(B)
1
st
quartile (upto 8.9) n = 30
7.3
4
th
vs 1
st
Quartile
.012
Exp(B) 0.362
(0.163, 0.802)
2
nd
quartile (8.9 to 11.9) n = 37
10.6
4
th
vs 2nd Quartile
.037
Exp(B) 0.485
(0.245, 0.959)
3
rd
quartile (11.9-15.6) n = 33
13.6
4
th
vs 3rd Quartile
.068
Exp(B) 0.509
(0.247, 1.052)
4
th
quartile ( = > 15.6) n = 31
18
Reference
5 organizations
2 drugs
2 targets
Organization
Nottingham University Hospitals NHS TrustOrganization
St Bartholomew's HospitalOrganization
Nottingham University Hospital NHS TrustOrganization
Royal United Hospitals Bath NHS Foundation TrustOrganization
University of NottinghamTarget
androgen receptorTarget
Androgen Receptors